TOP > 外国特許検索 > DOUBLE-STRANDED NUCLEIC ACID MOLECULE, DNA, VECTOR, CANCER CELL GROWTH INHIBITOR, CANCER CELL MIGRATION INHIBITOR, AND DRUG

DOUBLE-STRANDED NUCLEIC ACID MOLECULE, DNA, VECTOR, CANCER CELL GROWTH INHIBITOR, CANCER CELL MIGRATION INHIBITOR, AND DRUG

外国特許コード F160008775
整理番号 S2016-0061-N0
掲載日 2016年7月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP067054
国際公開番号 WO 2015190606
国際出願日 平成27年6月12日(2015.6.12)
国際公開日 平成27年12月17日(2015.12.17)
優先権データ
  • 特願2014-122067 (2014.6.13) JP
発明の名称 (英語) DOUBLE-STRANDED NUCLEIC ACID MOLECULE, DNA, VECTOR, CANCER CELL GROWTH INHIBITOR, CANCER CELL MIGRATION INHIBITOR, AND DRUG
発明の概要(英語) Provided is a double-stranded nucleic acid molecule for inhibiting the expression of non-coding RNA that includes base sequences represented by SEQ ID NOs: 1 to 4 or a portion of said base sequences, wherein the double-stranded nucleic acid molecule contains: (a) a sense strand that includes nucleotide sequences corresponding to target sequences represented by SEQ ID Nos. 5 to 11 or 26 to 31; and (b) an antisense strand that is complementary to the sense strand in (a) and forms a double strand with the sense strand.
特許請求の範囲(英語) [claim1]
1.  A plasmoid complex nuclear fusion reactor, the muon - - muon in order to obtain a nuclear fusion reaction plasmoid complex nuclear fusion reactor,  And the target container for ca1.  A double-stranded nucleic acid molecules for inhibiting the expression of non-coding RNA,  The double-stranded nucleic acid molecules, (A) SEQ ID NO: a sense strand containing from 5 to 11 and a nucleotide sequence corresponding to the target sequence represented by any one of 26-31, (B) comprises an antisense strand comprising a nucleotide sequence complementary to said sense strand to form the sense strand and double strand of said (a),  The non-coding RNA is, SEQ ID NO: double-stranded nucleic acid molecule which comprises at least one of the nucleotide sequences and portions thereof represented by 1-4.
[2]
[claim2]
2.  Sense strand, SEQ ID NO: 5,6,9,10,27,28,29,30, and claim 1 is the sense strand comprising a nucleotide sequence corresponding to the target sequence represented by any one of 31 double-stranded nucleic acid molecule.
[3]
[claim3]
3.  Sense strand, SEQ ID NO: 6, and double-stranded nucleic acid molecule according to any one of claims 1 to 2 is the sense strand comprising a nucleotide sequence corresponding to the target sequence represented by any one of 28.
[4]
[claim4]
4.  Double-stranded nucleic acid molecule according to any of claims 1 3 is either double-stranded RNA and double-stranded RNA-DNA chimera.
[claim5]
5.

Double-stranded nucleic acid molecule according to any of claims 1 4 is either siRNA and chimera siRNA.
[6]
[claim6]
6.  DNA which comprises a nucleotide sequence encoding a double-stranded nucleic acid molecule according to any one of claims 1 to 5.
[7]
[claim7]
7.  Vector comprising the DNA of claim 6.
[8]
[claim8]
8.  Double-stranded nucleic acid molecule according to any of claims 1 5, cancer cell proliferation suppressing agent which comprises at least one of the vectors described DNA, and claim 7 according to claim 6.
[9]
[claim9]
9.  Double-stranded nucleic acid molecule according to any one of claims 1 to 5, cancer cell migration inhibiting agent characterized in that it comprises at least one of the vectors described DNA, and claim 7 according to claim 6.
[10]
[claim10]
10.  A pharmaceutical for preventing or treating cancer, pharmaceutical, which comprises claims cancer cell growth inhibitor according to Item 8, and at least one cancer cell migration inhibitor according to claim 9.using a nuclear fusion reaction,  Is connected to the target container, and the solid hydrogen ice fog source for forming the incident solid hydrogen in the target container solid hydrogen ice fog,  Is connected to the target vessel, the magnetization plasmoid in the solid hydrogen ice fog in the target container as well as generate a magnetized plasmoid to transport, solid - and the plasmoid generation source for forming a plasma complex area,  And plasma muon source in order to obtain the incident nuclear reaction the muon in the composite area, - which is connected to the target container, solid  Muon characterized in that it comprises a - plasmoid complex fusion reactor.
[2]
[claim11]
2.  Muon according to claim 1 - in the plasmoid complex fusion reactor, the solid hydrogen ice fog sources and plasmoid generation sources, solid is generated - control as plasma complex area is maintained long time compared to the lifetime of the muon plasmoid complex fusion reactor - muons, characterized in that it is.
[3]
[claim12]
3.  Muon according to claim 1 or claim 2 - in the plasmoid complex fusion reactor, the plasmoid generating source, the magnetization plasmoid faster than the time scale of the plasma diffusion or relaxation, to transport in a solid hydrogen ice fog in the target container muon, characterized in that - plasmoid complex fusion reactor.
[4]
[claim13]
4.  Muon according to any one of claims 1 to 3 - the plasmoid complex fusion reactor, the muon generating source, muons characterized by incident muons while solid hydrogen ice fog is sublimated - plasmoid compound nucleus fusion reactor.
[5]
[claim14]
5.  Muon according to any one of claims 1 to 4 - A plasmoid composite nuclear fusion reactor, further connected to the target vessel, by including an energy transducer for recovering the fusion product plasmoid complex fusion reactor - muon characterized.
[6]
[claim15]
6.  Muons of claim 5 - In plasmoid complex fusion reactor, the plasmoid source is characterized by inducing the fusion product energy converter using a magnetic field to confine the generated magnetization plasmoid as a guide magnetic field muon - plasmoid complex fusion reactor.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAITAMA MEDICAL UNIVERSITY
  • 発明者(英語)
  • INOUE SATOSHI
  • IKEDA KAZUHIRO
  • INOUE KUNIKO
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close